Sydney Lupkin
speaker
1,064 appearances
108 recordings
3 series
first heard Dec 2024
last heard 4d ago
Sydney Lupkin’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 93 in all, peaking in Jul 2026 with 21.
Appearances
And some of them celebrated Gleevec's anniversary with him this past weekend.
Through a test program, the Centers for Medicare and Medicaid Services, or CMS, wanted health plans to voluntarily add obesity drug coverage for 2027.
But 80 percent of insurers had to sign on by April 20th, says Juliet Kubansky, a Medicare expert at the nonpartisan research group KFF.
A separate temporary program that would allow Medicare beneficiaries to get obesity drugs for $50 will still go into effect in July, but Kubansky says it will now have to last longer and could cost taxpayers billions.
Sydney Lepkin, NPR News.
Eli Lilly's new pill is called Fundeo.
Although this is the same company behind Zepbound, the blockbuster injectable obesity medicine, Eli Lilly decided not to take Zepbound's main ingredient and make it in pill form.
Instead, the company developed a new ingredient, Orfaglipron.
Daniel Skowronski, the company's chief scientific and medical officer, says until now, all of these GLP-1 drugs have been peptides, meaning they need to be taken as injections or as a pill with restrictions.
Lilly hasn't announced a list price yet, but it says people with commercial insurance could pay as little as $25 a month.
Sydney Lepkin, NPR News.
The FDA rattled the biotech industry when it said it wouldn't even look at Moderna's application to market the first mRNA flu shot.
Moderna used its mRNA technology to swiftly create and manufacture its COVID-19 shot during the pandemic.
The company wants to use the same technology to make a flu vaccine.
Initially, the FDA said it wouldn't review the new shot because the company didn't compare it to a high-dose flu vaccine in older people.
Now, Moderna says it will take an age-based approach and agreed to add a confirmatory study after marketing begins that will focus on older adults.
The company says the new vaccine would be ready for the next flu season pending FDA approval.
Sydney Lupkin, NPR News.
Vaccine maker Moderna says the FDA is refusing to consider approving the company's first flu vaccine, which also uses mRNA technology.
The FDA told the company the agency isn't satisfied with the company's study comparing Moderna's mRNA flu vaccine to a standard dose flu vaccine already on the market.
Showing 581–600 of 1,064 · page 30 of 54
← Previous
Next →